Vertex Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VRTX Vertex Pharmaceuticals Inc
CLB Core Laboratories NV
GTY Getty Realty Corp
FCX Freeport-McMoRan Inc
EFX Equifax Inc
CHKP Check Point Software Technologies Ltd
CTXS Citrix Systems Inc
RAKR Rainmaker Worldwide Inc
KERN Akerna Corp
T AT&T Inc
Go

Health Care : Biotechnology | Large Cap Growth
Company profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Price
Delayed
$210.14
Day's Change
-1.24 (-0.59%)
Bid
--
Ask
--
B/A Size
--
Day's High
214.74
Day's Low
209.95
Volume
(Light)

Today's volume of 696,092 shares is on pace to be much lighter than VRTX's 10-day average volume of 3,806,204 shares.

696,092
  • Prev Close
    211.38
  • Today's Open
    210.37
  • Day's Range
    209.95-214.74
  • Avg Vol (10-day)
    3.8M
  • Last (time)
    11:51a ET 10/22/20
  • Last (size)
    758
  • 52-Wk Range
    186.19 - 306.08
    LowHigh
  • (10/22/19 - 07/07/20)
    12.86%
  • 46.7%
  • Market Cap
    54.7B
  • Shares Outstanding
    260.5M
  • 7.91
  • 26.72x
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.7
  • 94.92
  • (% of float 09/30/20)
    1.30

Latest News

October 22, 2020
8:30 am ET
PR Newswire
October 19, 2020
4:01 pm ET
BusinessWire
October 15, 2020
7:31 am ET
MarketWatch
6:36 am ET
MarketWatch
October 14, 2020
5:08 pm ET
MarketWatch
5:07 pm ET
MarketWatch
4:30 pm ET
BusinessWire
9:00 am ET
BusinessWire
October 13, 2020
7:07 am ET
Globe Newswire
October 05, 2020
11:34 am ET
MarketWatch
September 25, 2020
8:00 am ET
BusinessWire
September 24, 2020
5:25 am ET
BusinessWire
September 22, 2020
9:00 am ET
Globe Newswire
September 16, 2020
4:30 pm ET
BusinessWire
5:28 am ET
Globe Newswire
September 14, 2020
4:15 am ET
BusinessWire
September 10, 2020
9:00 am ET
BusinessWire
3:57 am ET
BusinessWire
September 01, 2020
9:00 am ET
BusinessWire
August 21, 2020
9:07 am ET
BusinessWire
August 20, 2020
12:32 pm ET
BusinessWire
July 30, 2020
4:01 pm ET
BusinessWire
July 21, 2020
7:45 am ET
MarketWatch
June 24, 2020
7:42 am ET
MarketWatch
May 09, 2020
2:19 pm ET
MarketWatch
May 06, 2020
9:18 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.